RxDoctor Payments Data

Zemeng Luo

Family · San Francisco, CANPI 1659769073

Payments from drug & device makers

$4,030in general payments, 2019–2025

Across 86 payments — averaging $46.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$750
  • GSK$617
  • Gilead$347
  • Bayer$320
  • Lilly USA, LLC$280
  • Agios Pharmaceuticals, Inc.$257
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,030100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,030 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$33,969
Medicare patients
100
Services billed
431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$46,542
EliquisApixaban24$28,215
FarxigaDapagliflozin Propanediol24$27,679
TradjentaLinagliptin18$24,749
ProliaDenosumab13$21,099
VascepaIcosapent Ethyl14$5,202
Albuterol Sulfate HfaAlbuterol Sulfate70$3,443
Atorvastatin Calcium287$2,045
Losartan Potassium158$1,197
Omega-3 Acid Ethyl Esters20$1,013
Amlodipine Besylate127$598
Metoprolol Succinate58$581
Diclofenac Sodium36$497
Alendronate Sodium60$444
Metformin Hcl69$417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$96$71,29147 claims
PfizerEliquis$26$28,21524 claims
AstraZenecaFarxiga$136$27,67924 claims
AmgenProlia$750$21,09913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →